Professor and Chair
Obstetrics & Gynecology
Dr. Karen H. Lu, MD
|
|
Give Review
Dr. Karen H. Lu works in the field of Obstetrics & Gynecology. She researched medicine at Yale University School of Medicine. Yale University School of Medicine is a one of the best medicals schools. Yale University School of Medicine has a rank of 7 in research and a 57 in primary care She over the years received 4 awards: "America's Top Doctors", "Top Doctors:SE Texas", "America's Top Doctors for Cancer" and "Fellow (FACOG)". Karen is a published doctor and has 101 publications published. The lastest was: 'Phase I dose escalation study of temsirolimus in combination with metformin in patients with advanced/refractory cancers.' Karen H. Lu accepts Medicare.
Publications
- Loss of p27 Associated with Risk for Endometrial Carcinoma Arising in the Setting of Obesity.
- Common variants at the CHEK2 gene locus and risk of epithelial ovarian Cancer.
- Rethinking ovarian Cancer II: reducing mortality from high-grade serous ovarian Cancer.
- Management of nodal recurrences of endometrial Cancer with IMRT.
- One size may not fit all: The debate of universal tumor testing for Lynch Syndrome.
- Genotype-Phenotype Correlations by Ethnicity and Mutation Location in BRCA Mutation Carriers.
- Perioperative trajectory of patient reported symptoms: A pilot study in gynecologic oncology patients.
- Phase II Study of Everolimus and Letrozole in Patients With Recurrent Endometrial Carcinoma.
- A multiplexable, microfluidic platform for the rapid quantitation of a biomarker panel for early ovarian Cancer detection at the point-of-care.
- Clearer Picture of PMS2-Associated Lynch Syndrome Is Emerging.
- Evaluating the ovarian Cancer gonadotropin hypothesis: A candidate gene study.
- Hereditary colorectal Cancer syndromes: American Society of Clinical Oncology Clinical Practice Guideline endorsement of the familial risk-colorectal Cancer: European ...
- Combined colonoscopy and endometrial biopsy Cancer screening results in women with Lynch syndrome.
- Targeted PI3K/AKT/mTOR therapy for metastatic carcinomas of the cervix: A phase I clinical experience.
- Clinical Significance of CTNNB1 Mutation and Wnt Pathway Activation in Endometrioid Endometrial Carcinoma.
- Reply to D. Braun et al.
- Pathologic Findings at Risk-Reducing Salpingo-Oophorectomy: Primary Results From Gynecologic Oncology Group Trial GOG-0199.
- Evaluation of Clinical Criteria for the Identification of Lynch Syndrome among Unselected Patients with Endometrial Cancer.
- Loss of LKB1 in high-grade endometrial carcinoma: LKB1 is a novel transcriptional target of p53.
- Consequences of universal MSI/IHC in screening ENDOMETRIAL Cancer patients for lynch syndrome.
- Abnormal uterine bleeding as the presenting symptom of hematopoietic Cancer.
- Outcomes of patients with metastatic Cervical cancer in a phase I clinical trials program.
- CGRRF1 as a novel biomarker of tissue response to metformin in the context of obesity.
- Response to an exercise intervention after endometrial Cancer: Differences between obese and non-obese survivors.
- The Search Continues: Looking for Predictive Biomarkers for Response to Mammalian Target of Rapamycin Inhibition in Endometrial Cancer.
- Underestimation of Risk of a BRCA1 or BRCA2 Mutation in Women With High-Grade Serous Ovarian Cancer by BRCAPRO: A Multi-Institution Study.
- Advanced gynecologic malignancies treated with a combination of the VEGF inhibitor bevacizumab and the mTOR inhibitor temsirolimus.
- Quality of Cancer Family History and Referral for Genetic Counseling and Testing Among Oncology Practices: A Pilot Test of Quality Measures As Part of the American Soc...
- American Society of Clinical Oncology Expert Statement: Collection and Use of a Cancer Family History for Oncology Providers.
- Acceptability of prophylactic salpingectomy with delayed oophorectomy as risk-reducing surgery among BRCA mutation carriers.
- Another Surprise from Metformin: Novel Mechanism of Action via K-Ras Influences Endometrial Cancer Response to Therapy.
- Risk perception, worry, and test acceptance in average-risk women who undergo ovarian Cancer screening.
- Gynecologic Cancer InterGroup (GCIG) Endometrial Cancer Clinical Trials Planning Meeting: Taking Endometrial Cancer Trials Into the Translational Era.
- Outcomes of screening endometrial Cancer patients for Lynch syndrome by patient-administered checklist.
- A 2-stage ovarian Cancer screening strategy using the Risk of Ovarian Cancer Algorithm (ROCA) identifies early-stage incident Cancers and demonstrates high positive pr...
- Comparison of attitudes regarding preimplantation genetic diagnosis among patients with hereditary Cancer syndromes.
- Molecular pathogenesis of endometrial Cancers in patients with Lynch syndrome.
- Prospective Multicenter Randomized Intermediate Biomarker Study of Oral Contraceptive versus Depo-Provera for Prevention of Endometrial Cancer in Women with Lynch Synd...
- Utility of MLH1 Methylation Analysis in the Clinical Evaluation of Lynch Syndrome in Women with Endometrial Cancer.
- Gynecologic Cancer screening and communication with health care providers in women with Lynch syndrome.
- Genome-Wide Association Study in BRCA1 Mutation Carriers Identifies Novel Loci Associated with Breast and Ovarian Cancer Risk.
- Chemopreventive effects of metformin on obesity-associated endometrial proliferation.
- Self-administration of propofol is mediated by dopamine D1 receptors in nucleus accumbens in rats.
- A prospective phase II study of chemoradiation followed by adjuvant chemotherapy for FIGO stage I-IIIA (1988) Uterine papillary serous carcinoma of the endometrium.
- Genotype in BRCA-associated Breast Cancers.
- Whole-exome sequencing combined with functional genomics reveals novel candidate driver Cancer genes in endometrial Cancer.
- Cancer spectrum in DNA mismatch repair gene mutation carriers: results from a hospital based Lynch syndrome registry.
- Assessing the added value of breast tumor markers in genetic risk prediction model BRCAPRO.
- Peritoneal washing cytology in patients with BRCA1 or BRCA2 mutations undergoing risk-reducing salpingo-oophorectomies: A 10-year experience and reappraisal of its cli...
- Genetic risk and gynecologic Cancers.
- Omental adipose tissue-derived stromal cells promote vascularization and growth of endometrial tumors.
- Roles of genetic variants in the PI3K and RAS/RAF pathways in susceptibility to endometrial Cancer and clinical outcomes.
- Reclassification of serous Ovarian carcinoma by a 2-tier system: A Gynecologic Oncology Group Study.
- High Frequency of PIK3R1 and PIK3R2 Mutations in Endometrial Cancer Elucidates a Novel Mechanism for Regulation of PTEN Protein Stability.
- Proteomic biomarkers in combination with CA 125 for detection of epithelial ovarian Cancer using prediagnostic serum samples from the prostate, lung, colorectal, and o...
- Proteomic biomarkers apolipoprotein A1, truncated transthyretin and connective tissue activating protein III enhance the sensitivity of CA125 for detecting early stage...
- Satisfaction with Ovarian carcinoma risk-reduction strategies among women at high risk for breast and Ovarian carcinoma.
- Understanding obesity and endometrial Cancer risk: opportunities for prevention.
- Testing women with endometrial Cancer to detect lynch syndrome.
- The Anterior Gradient Homolog 3 (AGR3) Gene Is Associated With Differentiation and Survival in Ovarian Cancer.
- Improved survival in non-Ashkenazi Jewish ovarian Cancer patients with BRCA1 and BRCA2 gene mutations.
- Prospective evaluation of insulin resistance among endometrial Cancer patients.
- Ovarian Cancer biomarker performance in prostate, lung, colorectal, and ovarian Cancer screening trial specimens.
- Microscopic and early-stage ovarian Cancers in BRCA1/2 mutation carriers: building a model for early BRCA-associated tumorigenesis.
- Circulating adiponectin levels and risk of endometrial Cancer: the prospective Nurses' Health Study.
- Is low-grade serous ovarian Cancer part of the tumor spectrum of hereditary breast and ovarian Cancer?
- A clinical perspective on genetic counseling and testing during end of life care for women with recurrent progressive ovarian Cancer: opportunities and challenges.
- A phase 2 study of the oral mammalian target of rapamycin inhibitor, everolimus, in patients with recurrent endometrial carcinoma.
- BRAF mutation is rare in advanced-stage low-grade Ovarian serous carcinomas.
- Expanding the criteria for BRCA mutation testing in breast Cancer survivors.
- Somatic mutations in BRCA1 and BRCA2 could expand the number of patients that benefit from poly (ADP ribose) polymerase inhibitors in ovarian Cancer.
- Evaluating women with ovarian Cancer for BRCA1 and BRCA2 mutations: missed opportunities.
- Preventing future Cancers by testing women with ovarian Cancer for BRCA mutations.
- Primary peritoneal Cancer after bilateral salpingo-oophorectomy in two patients with Lynch syndrome.
- Messenger RNA expression and methylation of candidate tumor-suppressor genes and risk of ovarian Cancer-a case-control analysis.
- Molecular clustering of endometrial carcinoma based on estrogen-induced gene expression.
- The monkey, the hen, and the mouse: models to advance ovarian Cancer chemoprevention.
- PAX2 expression in low malignant potential Ovarian tumors and low-grade Ovarian serous carcinomas.
- Timing of BRCA1/BRCA2 genetic testing in women with ovarian Cancer.
- MEKK3 expression correlates with nuclear factor kappa B activity and with expression of antiapoptotic genes in serous Ovarian carcinoma.
- Endometrial Cancer in an adolescent: a possible manifestation of Cowden syndrome.
- Recurrent low-grade serous Ovarian carcinoma is relatively chemoresistant.
- Perception of screening and risk reduction surgeries in patients tested for a BRCA deleterious mutation.
- Management of early-stage endometrial Cancer.
- Physical activity and obesity in endometrial Cancer survivors: associations with pain, fatigue, and physical functioning.
- Accuracy of the BRCAPRO model among women with bilateral breast Cancer.
- Enhanced estrogen-induced proliferation in obese rat endometrium.
- Endometrial Cancer and Lynch syndrome: clinical and pathologic considerations.
- Carcinoma of the lower uterine segment: a newly described association with Lynch Syndrome.
- Limited public knowledge of obesity and endometrial Cancer risk: what women know.
- What women with ovarian Cancer think and know about genetic testing.
- Cost-effectiveness analysis of prevention strategies for gynecologic Cancers in Lynch syndrome.
- Cost-effectiveness analysis of endometrial Cancer prevention strategies for obese women.
- Loss of Tuberous sclerosis complex-2 function and activation of mammalian target of rapamycin signaling in endometrial carcinoma.
- Gene expression changes in Cervical squamous cell carcinoma after initiation of chemoradiation and correlation with clinical outcome.
- Imprinted tumor suppressor genes ARHI and PEG3 are the most frequently down-regulated in human ovarian Cancers by loss of heterozygosity and promoter methylation.
- Prospective determination of prevalence of lynch syndrome in young women with endometrial Cancer.
- BRCA1 and BRCA2 genetic testing in Hispanic patients: mutation prevalence and evaluation of the BRCAPRO risk assessment model.
- Survivors of gynecologic malignancies: impact of treatment on health and well-being.
- Phase I dose escalation study of temsirolimus in combination with metformin in patients with advanced/refractory Cancers.
Schools
Yale Univ Sch Of Med
Brigham and Women39s Hospital
Procedures Preformed
- Colposcopy
- Excision, Shaving, or Destruction of Skin and Subcutaneous Tissue (incl. Mohs Micrographic Surgery), Tissue Transfer
- Gynecologic Cancer Screening
- Hysterectomy - Laparoscopic
- View All
Conditions Treated
- Asymptomatic Post-Menopausal Status
- Atrophic Vaginitis
- Cervical Cancer
- Cervicitis
- View All
Doctors Specialties
- Gynecologic Oncology
- Obstetrics
- Gynecology
Accepted Insurances
Awards
- America's Top Doctors
- Top Doctors:SE Texas
- America's Top Doctors for Cancer
- Fellow (FACOG)
Education
-
Brigham and Women's Hospital -
Yale University School of Medicine
Hospital
-
University of Texas M.D. Anderson Cancer Center
Drug Facts
| NPI NUMBER | 1235286709 | |
| NPPES Provider LastName | LU | |
| NPPES Provider FirstName | KAREN | |
| NPPES Provider ZIPCode | 770304009 | |
| NPPES Provider State | TX | |
| Specialty Description | Obstetrics/Gynecology | |
| Total Claim Count | 62.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1235286709 |
| Last Name Of The Provider | LU |
| First Name Of The Provider | KAREN |
| View All |
Similar Doctors
|
Dr. Erica A. Roberts, MD
 This Doctor is OpenDoctor Recommended.
|
|
Dr. Rebecca C. Luethcke, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Creighton L. Edwards, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Alexandra Pellicena, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Timothy B. Waterhouse, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Xiaoming Guan, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Pedro T. Ramirez, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Cecilia T. Valdes, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Susan P. Raine, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Earl J. Lombard, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Judith K. Wolf, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Robert H. Barr Sr., MD |